Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a keen interest in the study's potential, highlighted by phrases like 'aimed at how MCED integrates in standards of care' and references to detailed data such as 'PPV 44.6%' and participant risks. The tone shows cautious optimism, balancing enthusiasm with acknowledgment of the ongoing nature of research, which explains the moderate scores across engagement and impact.
Most discussions acknowledge the significance of the PATHFINDER study and its potential for early cancer detection, though some remain cautiously optimistic rather than fully endorsing it.
The social discussions demonstrate high interest, referencing detailed aspects of the study like signal percentages, prevalence, and integration into clinical practice.
Participants reference specific details such as the study's methodology, participant risk factors, and ongoing related research, indicating moderate depth of engagement.
Discussions suggest recognition of potential transformative effects on screening and diagnosis but also highlight that results are preliminary and part of ongoing research, implying moderate perceived impact.
@sbarnettARK The PATHFINDER study, of the GRAIL cfDNA + methylation, will roll-up the results of STRIVE (BrCa screen) & SUMMIT (high risk lung), both ongoing. So not yet demo'd. But aimed at how MCED integrates in standards of care. https://t.co/4JWAVistL4
Wood #AACR23 Grail's Pathfinder study. 6200 participants, 15 institutions. Age >50, history of cancer or smoking, another group average risk. 2021 ref https://t.co/ljSzGdpM6o Overall signal 1.4%; high risk 1.5%. PPV 44.6%, 57.1% in high risk. Most with Dx resolution 57/63
@Dr_PJEdwards @CanTest_PC @CRUKresearch @CaPRINetwork @BoomboomchiefsT @richarddneal @fmw22 @GLyratzopoulos @BrianDNicholson @drtomround @FunstonGarth Hi @Dr_PJEdwards Some papers https://t.co/gb72oClQGT https://t.co/WVY7zEvHJC Try these sites https://t.co/xhmSdcaZBD https://t.co/vl6CPWVc41
New article: The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice https://t.co/pASGYQmj0W #kidneycancer #oncology https://t.co/JnRJGEFmrz
This video explores a multicancer early detection test using methylation-based sequencing of cell-free DNA in blood, aiming to improve early cancer diagnosis and integration into clinical practice.
The PATHFINDER study evaluates a new blood test based on methylated cell-free DNA for early detection of multiple cancers in individuals aged 50 and above. This clinical trial assesses test accuracy, follow-up…
https://t.co/4thOXpm25p #prime2 Nadauld LD, ..., Marinac CR (Cancers (Basel)) __The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice__ https://t.co/8lzquB0LNq
Wood #AACR23 Grail's Pathfinder study. 6200 participants, 15 institutions. Age >50, history of cancer or smoking, another group average risk. 2021 ref https://t.co/ljSzGdpM6o Overall signal 1.4%; high risk 1.5%. PPV 44.6%, 57.1% in high risk. Most with Dx resolution 57/63
@Dr_PJEdwards @CanTest_PC @CRUKresearch @CaPRINetwork @BoomboomchiefsT @richarddneal @fmw22 @GLyratzopoulos @BrianDNicholson @drtomround @FunstonGarth Hi @Dr_PJEdwards Some papers https://t.co/gb72oClQGT https://t.co/WVY7zEvHJC Try these sites https://t.co/xhmSdcaZBD https://t.co/vl6CPWVc41
@sbarnettARK The PATHFINDER study, of the GRAIL cfDNA + methylation, will roll-up the results of STRIVE (BrCa screen) & SUMMIT (high risk lung), both ongoing. So not yet demo'd. But aimed at how MCED integrates in standards of care. https://t.co/4JWAVistL4
New article: The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice https://t.co/pASGYQmj0W #kidneycancer #oncology https://t.co/JnRJGEFmrz